After 20 years, Human Genome Sciences nears profitability

With the recent approval of potential blockbuster lupus drug Benlysta, Human Genome Sciences ($HGSI) is on track to generate 'meaningful' revenue for the first time in its almost 20-year history. It has to share sales of the drug with marketing partner GlaxoSmithKline, explains Motley Fool scribe Brian Orelli, and will continue spending hundreds of millions on ramping up its sales force and supporting further R&D of the drug. Orelli expects the developer to actually begin showing a profit in 2013. Article

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.